Primary Care Physician Perspectives on Barriers to Statin Treatment

Cardiovascular Drugs and Therapy

Volumn 31, Issue 3, 2017, Pages 303-309

  Tanner, Rikki M ^a   Safford, Monika M ^b   Monda, Keri L ^c   Taylor, Benjamin ^c   O’Beirne, Ronan ^d   Morris, Melanie ^d   Colantonio, Lisandro D ^a   Dent, Ricardo ^e   Muntner, Paul ^a   Rosenson, Robert S ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e Esperion Therapeutics Inc   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Discontinuation; Nominal groups; Qualitative research; Re challenge; Side effects; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTINUING EDUCATION; DIARRHEA; FATIGUE; FEAR; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HUMAN; MEDICAL EDUCATION; MEDICAL PRACTICE; MENTAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ECONOMICS; FEMALE; MALE; MIDDLE AGED;

ADULT; AGED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHYSICIANS, PRIMARY CARE;

EID: 85023754493     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-017-6738-x     Document Type: Article

References (28)

1. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816.
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.
3. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.
4. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526–34.
5. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166(3):597–603.
6. Eaton CB, Galliher JM, McBride PE, Bonham AJ, Kappus JA, Hickner J. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. JABFM. 2006;19(1):46–53.
7. Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying medications: differentiating “clinical inertia” from appropriate care. J Gen Int Med. 2007;22(12):1648–55.
8. Shewchuk R, O'Connor SJ. Using cognitive concept mapping to understand what health care means to the elderly: an illustrative approach for planning and marketing. Health Mark Q. 2002;20(2):69–88.
9. Levine DA, Saag KG, Casebeer LL, Colon-Emeric C, Lyles KW, Shewchuk RM. Using a modified nominal group technique to elicit director of nursing input for an osteoporosis intervention. J Am Med Dir Assoc. 2006;7(7):420–5.
10. Van de Ven AH, Delbecq AL. The nominal group as a research instrument for exploratory health studies. Am J Public Health. 1972;62(3):337–42.
11. Hickling JA, Nazareth I, Rogers S. The barriers to effective management of heart failure in general practice. Brit J Gen Pract. 2001;51(469):615–8.
12. Delbecq AL, Van de Ven AH. A group process model for problem identification and program planning. J Appl Behav Sci. 1971;7(4)
13. Van Breda A. Steps to analysing multiple-group NGT data. Soc Work Pract Res. 2005;17(1):1–14.
14. Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995;76(9):54C–9C.
15. Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010;13(3):428–37.
16. Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmaco Economics. 2008;26(4):329–39.
17. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83.
18. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.
19. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The National Lipid Association’s Muscle Safety Expert Panel: an assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71.
20. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6–15.
21. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90.
22. Evans WJ, Cannon JG. The metabolic effects of exercise-induced muscle damage. Exerc Sport Sci Rev. 1991;19:99–125.
23. Rojas-Fernandez C, Hudani Z, Bittner V. Statins and cognitive side effects: what cardiologists need to know. Endocrinol Metab Clin N Am. 2016;45(1):101–16.
24. Samaras K, Brodaty H, Sachdev PS. Does statin use cause memory decline in the elderly? Trends Cardiovasc Med. 2016;26(6):550–65.
25. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24(5):584–91.
26. Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85(4):349–56.
27. Boehme AK, Davies SL, Moneyham L, Shrestha S, Schumacher J, Kempf MC. A qualitative study on factors impacting HIV care adherence among postpartum HIV-infected women in the rural southeastern USA. AIDS Care. 2014;26(5):574–81.
28. Becker WC, Dorflinger L, Edmond SN, Islam L, Heapy AA, Fraenkel L. Barriers and facilitators to use of non-pharmacological treatments in chronic pain. BMC Fam Pract. 2017;18(1):41.